Anticancer drugs targeting angiogenesis act either directly on vascular endothelial growth factor (VEGF) receptors (VEGF inhibitors) or VEGF-mediated intracellular processes (tyrosine kinase inhibitors) or indirectly through downstream VEGF signaling within broader processes (mammalian target of rapamycin inhibitors and multiprotein kinase inhibitors). Although VEGF blockade may be implicated in arterial wall injuries, the literature on the association between antiangiogenic drugs and artery dissections or aneurysms is scant, comprising only a few case reports and 1 pharmacovigilance study conducted in Japan.1 The present study evaluated the association between all antiangiogenic drugs and dissections or aneurysms occurring in all arteries.< Leer menos

Metadatos

Compartir este ítem

Licencia de uso del documento

Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms

Idioma

Este ítem está publicado en

Resumen en inglés

URI

DOI

Centros de investigación